Loading...
InnoCare Pharma Limited
INCPF•PNK
Healthcare
Biotechnology
$3.26
$0.00(0.00%)
InnoCare Pharma Limited (INCPF) Financial Performance & Income Statement Overview
Review InnoCare Pharma Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
36.68%
↑ 36.68%
Operating Income Growth
18.36%
↑ 18.36%
Net Income Growth
30.20%
↑ 30.20%
Operating Cash Flow Growth
45.55%
↑ 45.55%
Operating Margin
-74.59%
↓ 74.59%
Gross Margin
82.02%
↑ 82.02%
Net Profit Margin
-58.57%
↓ 58.57%
ROE
-5.15%
↓ 5.15%
ROIC
-6.09%
↓ 6.09%
InnoCare Pharma Limited (INCPF) Income Statement & Financial Overview
Review InnoCare Pharma Limited's (INCPF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $311.70M | $278.01M | $253.91M | $165.82M |
| Cost of Revenue | $40.41M | $37.89M | $35.85M | $24.29M |
| Gross Profit | $271.29M | $240.12M | $218.06M | $141.53M |
| Gross Profit Ratio | $0.87 | $0.86 | $0.86 | $0.85 |
| R&D Expenses | $199.04M | $193.58M | $243.68M | $177.73M |
| SG&A Expenses | $188.15M | $157.64M | $110.85M | $131.94M |
| Operating Expenses | -$14.00M | $257.49M | $340.29M | $287.19M |
| Total Costs & Expenses | $26.42M | $295.38M | $376.14M | $311.48M |
| Interest Income | $0.00 | $0.00 | $47.43M | $47.13M |
| Interest Expense | $0.00 | $0.00 | $5.21M | $5.18M |
| Depreciation & Amortization | $14.50M | $14.50M | $0.00 | $14.50M |
| EBITDA | -$100.49M | -$85.53M | -$116.98M | -$147.36M |
| EBITDA Ratio | -$0.32 | -$0.31 | -$0.46 | -$0.89 |
| Operating Income | $285.28M | -$17.37M | -$122.22M | -$161.86M |
| Operating Income Ratio | $0.92 | -$0.06 | -$0.48 | -$0.98 |
| Other Income/Expenses (Net) | -$452.59M | $1031.00 | -$38144.00 | $31003.00 |
| Income Before Tax | -$167.30M | -$17.37M | -$122.26M | -$145.66M |
| Income Before Tax Ratio | -$0.54 | -$0.06 | -$0.48 | -$0.88 |
| Income Tax Expense | $234581.00 | $30.00 | $28979.00 | $20.00 |
| Net Income | -$165.22M | -$13.57M | -$119.44M | -$142.40M |
| Net Income Ratio | -$0.53 | -$0.05 | -$0.47 | -$0.86 |
| EPS | -$0.10 | -$0.007 | -$0.08 | -$0.08 |
| Diluted EPS | -$0.10 | -$0.007 | -$0.08 | -$0.08 |
| Weighted Avg Shares Outstanding | $1.60B | $1.89B | $1.49B | $1.78B |
| Weighted Avg Shares Outstanding (Diluted) | $1.60B | $1.89B | $1.49B | $1.78B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan